Tuberculosis and HIV coinfection and related collaborative activities in Latin America and the Caribbean

Objective. To inform about the most recent epidemiological trends and integrated programmatic response to tuberculosis (TB) and HIV coinfection in Latin America and the Caribbean (LAC). Methods. A descriptive review analyzed the most relevant indicators on TB/HIV coinfection in 33 countries in LAC w...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Ralfh Moreno (Egilea), Giovanni Ravasi (Egilea), Pedro Avedillo (Egilea), Rafael Lopez (Egilea)
Formatua: Liburua
Argitaratua: Pan American Health Organization, 2020-05-01T00:00:00Z.
Gaiak:
Sarrera elektronikoa:Connect to this object online.
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_0b29fea8dcdb4da68e24ab9225e5f57c
042 |a dc 
100 1 0 |a Ralfh Moreno  |e author 
700 1 0 |a Giovanni Ravasi  |e author 
700 1 0 |a Pedro Avedillo  |e author 
700 1 0 |a Rafael Lopez  |e author 
245 0 0 |a Tuberculosis and HIV coinfection and related collaborative activities in Latin America and the Caribbean 
260 |b Pan American Health Organization,   |c 2020-05-01T00:00:00Z. 
500 |a 1020-4989 
500 |a 1680-5348 
500 |a 10.26633/RPSP.2020.43 
520 |a Objective. To inform about the most recent epidemiological trends and integrated programmatic response to tuberculosis (TB) and HIV coinfection in Latin America and the Caribbean (LAC). Methods. A descriptive review analyzed the most relevant indicators on TB/HIV coinfection in 33 countries in LAC with a cross-sectional and time-trend approach. Data were obtained from publicly available databases and analyzed through simple proportions, weighted means, and risk ratios. Results. In LAC, during 2017, 80.8% of TB patients were actively screened for HIV, with a 25.6% increase between 2011 and 2017. In the same year, the proportion of TB patients with HIV-positive status was 11.2%, with a small but progressive reduction of 5% since 2011. The provision of antiretroviral therapy and anti-TB medication among TB/HIV coinfected patients for 2017 was at 60%. Only one-third of people living with HIV had access to isoniazid preventive therapy. Overall, the mortality in the TB/HIV cohort has not changed since 2012, hovering at around 20%. Conclusions. TB/HIV collaborative activities, as the backbone to address TB/HIV coinfection, are being scaled up in LAC and some indicators show a tendency toward improvement; nevertheless, our review shed light on the need to keep strengthening integration of service delivery, joint monitoring and evaluation, and data quality. 
546 |a EN 
546 |a ES 
546 |a PT 
690 |a hiv 
690 |a tuberculosis 
690 |a coinfection 
690 |a health policy 
690 |a latin america 
690 |a Medicine 
690 |a R 
690 |a Arctic medicine. Tropical medicine 
690 |a RC955-962 
690 |a Public aspects of medicine 
690 |a RA1-1270 
655 7 |a article  |2 local 
786 0 |n Revista Panamericana de Salud Pública, Vol 44, Iss 43, Pp 1-9 (2020) 
787 0 |n https://iris.paho.org/handle/10665.2/52085 
787 0 |n https://doaj.org/toc/1020-4989 
787 0 |n https://doaj.org/toc/1680-5348 
856 4 1 |u https://doaj.org/article/0b29fea8dcdb4da68e24ab9225e5f57c  |z Connect to this object online.